Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus

Atsumi,Satoru; Matsumine,Akihiko; Toyoda,Hidemi; Niimi,Rui; Iino,Takahiro; Nakamura,Tomoki; Matsubara,Takao; Asanuma,Kunihiro; Komada,Yoshihiro; Uchida,Atsumasa; Sudo,Akihiro

doi:10.3892/ijo.2012.1514

Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus

Authors:
- Satoru Atsumi
- Akihiko Matsumine
- Hidemi Toyoda
- Rui Niimi
- Takahiro Iino
- Tomoki Nakamura
- Takao Matsubara
- Kunihiro Asanuma
- Yoshihiro Komada
- Atsumasa Uchida
- Akihiro Sudo
View Affiliations

Affiliations: Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan, Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
Published online on: June 12, 2012 https://doi.org/10.3892/ijo.2012.1514
Pages: 893-902

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The poliovirus receptor CD155, is essential for poliovirus to infect and induce death in neural cells. Recently, CD155 has been shown to be selectively expressed on certain types of tumor cells originating from the neural crest, including malignant glioma and neuroblastoma. However, the expression pattern of CD155 in soft tissue sarcoma has not been examined. Therefore, we first examined CD155 expression in sarcoma cell lines, and found the expression of both CD155 mRNA and protein in 12 soft and bone tissue sarcoma cell lines. Furthermore, we examined the effect of live attenuated poliovirus (LAPV) on 6 bone and soft tissue sarcoma cell lines in vitro, and found that LAPV induced apoptosis by activating caspases 7 and 3 in all of these cell lines. Furthermore, in BALB/c nu/nu mice xenotransplanted with HT1080 fibrosarcoma cells, administration of live attenuated poliovirus caused growth suppression of the tumors. These results suggest that oncolytic therapy using a LAPV may represent a new option for the treatment of bone and soft tissue sarcomas.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 60:277–300. 2010.
2.	Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH and Brennan MF: Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 229:602–610. 1999. View Article : Google Scholar : PubMed/NCBI
3.	Gilbert NF, Cannon CP, Lin PP and Lewis VO: Soft-tissue sarcoma. J Am Acad Orthop Surg. 17:40–47. 2009.PubMed/NCBI
4.	Clark MA, Fisher C, Judson I and Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med. 353:701–711. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Grimer R, Judson I, Peake D and Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma: May 31, 2010 (Epub ahead of print). doi: 10.1155/2010/506182.
6.	No authors listed. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 350:1647–1654. 1997. View Article : Google Scholar : PubMed/NCBI
7.	Gortzak E, Azzarelli A, Buesa J, et al: A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 37:1096–1103. 2001.
8.	Sinkovics JG and Horvath JC: New developments in the virus therapy of cancer: a histrogical review. Intervirology. 36:193–214. 1993.PubMed/NCBI
9.	Sinkovics JG and Horvath JC: Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz). 56(Suppl 1): 3s–59s. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Parato KA, Senger D, Forsyth PA and Bell JC: Recent progress in the between oncolytic viruses and tumors. Nat Rev Cancer. 5:965–976. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Coffey MC, Storong JE, Forsyth PA and Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science. 282:1332–1334. 1998. View Article : Google Scholar : PubMed/NCBI
12.	Sinkovics JG and Horvath JC: Newcastle disease virus (NDV): brief history of its oncolytic strain. J Clin Virol. 16:1–15. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Springfeld C, Fielding AK, Peng KW, Galanis E, Russell SJ and Cattaneo R: Measles virus: improving natural oncolytic properties by genetic engineering. Viral Therapy of Human Cancers. Sinkovics JG and Horvath JC: Marcel Dekker Inc; New York, NY: pp. 459–480. 2005
14.	Stojdl DF, Litchy B, Knowles S, Marius R, Atkins H, Sonenberg N and Bell JC: Exploiting tumor-specific defects in interferon pathway with a previously unknown oncolytic virus. Nat Med. 6:821–825. 2000. View Article : Google Scholar : PubMed/NCBI
15.	Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH and Wimmer E: Intergenic poliovirus recombinants for treatment of malignant glioma. Proc Natl Acad Sci USA. 97:6803–6808. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Bodian D: Poliomyelitis. Pathology of the Nervous System. Minckler J: McGraw-Hill; New York, NY: pp. 2323–2344. 1972
17.	Ren R, Costantini F, Gorgacz EJ, Lee JJ and Racaniello VR: Transgenic mice expressing a human poliovirus receptor: a newmodel for poliomyelitis. Cell. 63:353–362. 1990. View Article : Google Scholar : PubMed/NCBI
18.	Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H and Nomoto A: Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA. 88:951–955. 1991. View Article : Google Scholar
19.	Gromeier M, Alexander L and Wimmer E: Internal ribosomal entry site substitution eliminates neurovirulence in intergenic poliovirus recombinants. Proc Natl Acad Sci USA. 93:2370–2375. 1996. View Article : Google Scholar : PubMed/NCBI
20.	Kauder SE and Racaniello VR: Internal ribosomal entry site substitution eliminates neurovirulence in intergenic poliovirus recombinants. Proc Natl Acad Sci USA. 93:2370–2375. 1996. View Article : Google Scholar : PubMed/NCBI
21.	Takai Y, Miyoshi J, Ikeda W and Ogita H: Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 9:603–615. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Amano H, Ikeda W, Kawano S, et al: Interaction and localization of Necl-5 and PDGF receptor beta at the leading edges of moving NIH3T3 cells: implications for directional cell movement. Genes Cells. 13:269–284. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD and Gromeier M: Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol. 6:208–217. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Toyoda H, Hayashi T, Gabbazza EC, et al: Experimental treatment of human neuroblastoma using live-attenuated poliovirus. Int J Oncol. 24:49–58. 2004.PubMed/NCBI
25.	Nobis P, Zibirre R, Meyer G, Kuhne J, Warnecke G and Koch G: Production of a monoclonal antibody against an epitope on HeLa cells that is the functional poliovirus binding site. J Gen Virol. 66:2563–2569. 1985. View Article : Google Scholar : PubMed/NCBI
26.	Wakabayashi T, Matsumine A, Nakazora S, et al: Fibulin-3 negatively regulates chondrocyte differentiation. Biochem Biophys Res Commun. 391:1116–1121. 2010. View Article : Google Scholar : PubMed/NCBI
27.	Kono T, Imai Y, Yasuda S, et al: The CD155/poliovirus receptor enhances the proliferation of ras-mutated cells. Int J Cancer. 122:317–324. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Tomayko MM and Reynald CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cance Chemother Pharmacol. 24:148–154. 1989. View Article : Google Scholar : PubMed/NCBI
29.	Mendelsohn CL, Wimmer E and Racaniello VR: Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 56:855–865. 1989. View Article : Google Scholar : PubMed/NCBI
30.	Grimer R, Athanasou N, Gerrand C, et al: UK Guidelines for the Management of Bone Sarcomas. Sarcoma: Dec 29, 2010 (Epub ahead of print). doi: 10.1155/2010/317462.
31.	Solecki D, Wimmer E, Lipp M and Bernhardt G: Identification and characterization of the cis-acting elements of the human CD155 gene core promoter. J Biol Chem. 274:1791–1800. 1999. View Article : Google Scholar : PubMed/NCBI
32.	Solecki D, Bernhardt G, Lipp M and Wimmer E: Identification of nuclear respiratory factor-1 binding site within the core promoter of polio virus receptor/ CD155 gene. J Biol Chem. 275:12453–12462. 2000. View Article : Google Scholar : PubMed/NCBI
33.	Marsson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P and Denis MG: Overexpression of CD155 gene in human colorectal cartinoma. Gut. 49:236–240. 2001. View Article : Google Scholar : PubMed/NCBI
34.	Solecki DJ, Gromeier M, Mueller S, Bernhardt G and Wimmer E: Expression of the human poliovirus receptor/ CD155 gene is activated by sonic hedgehog. J Biol Chem. 277:25697–25702. 2002. View Article : Google Scholar : PubMed/NCBI
35.	Li F, Shi W, Capurro M and Filmus J: Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol. 192:691–704. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Oue T, Yoneda A, Uehara S, Yamanaka H and Fukuzawa M: Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg. 45:387–392. 2010. View Article : Google Scholar : PubMed/NCBI
37.	Minami Y, Ikeda W, Kajita M, Fujito T, Monden M and Takai Y: Involvement of up-regulated Necl-5/Tage4/PVR/CD155 in the loss of contact inhibition in transformed NIH3T3 cells. Biochem Biophys Res Commun. 352:856–860. 2007. View Article : Google Scholar : PubMed/NCBI
38.	Toyoda H, Franco D, Fujita K, Paul AV and Wimmer E: Replication of poliovirus requires binding of the poly(rC) binding protein to cloverleaf as well as to the adjacent C-rich spacer sequence between the cloverleaf and the internal ribosomal entry site. J Virol. 81:10017–10028. 2007. View Article : Google Scholar : PubMed/NCBI
39.	Gosselin AS, Simonin Y, Guivel-Benhassine F, et al: Poliovirus-induced apoptosis is reduced in cell expressing a mutant CD155 selected during presistant poliovirus infection in neuroblastoma cells. J Virol. 77:790–798. 2003. View Article : Google Scholar : PubMed/NCBI
40.	Whitton JL, Cornell CT and Feuer R: Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol. 3:765–776. 2005. View Article : Google Scholar : PubMed/NCBI
41.	Ida-Hosonuma M, Iwasaki T, Yoshikawa T, et al: The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol. 79:4460–4469. 2005. View Article : Google Scholar : PubMed/NCBI
42.	Melnick JL: Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. Virology. Fields BN, Knipe DM, Howley PM, et al: Raven Press; New York, NY: pp. 549–605. 1995
43.	Yang WX, Terasaki T, Shiroki K, et al: Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor. Virology. 229:421–428. 1997. View Article : Google Scholar : PubMed/NCBI
44.	Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RM and Cochi SL: Intramuscular injections within 30 days of immunization with oral poliovirus vaccine - a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med. 332:500–506. 1995. View Article : Google Scholar
45.	Ohka S, Matsuda N, Tohyama K, Oda T, Morikawa M, Kuge S and Nomoto A: Receptor(CD155)-dependent endocytosis of poliovirus and retrograde axonal transport of the endosome. J Virol. 78:7186–7198. 2004. View Article : Google Scholar : PubMed/NCBI
46.	Gromeier M and Wimmer E: Mechanism of injury-provoked poliomyelitis. J Virol. 72:5056–5060. 1998.PubMed/NCBI
47.	Ochs K, Zeller A, Saleh L, Bassili G, Song Y, Sonntag A and Niepmann M: Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J Virol. 77:115–122. 2003. View Article : Google Scholar : PubMed/NCBI
48.	Toyoda H, Yin J, Mueller S, Wimmer E and Cello J: Oncolytic treatment and care of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res. 67:2857–2864. 2007. View Article : Google Scholar : PubMed/NCBI
49.	Porosnicu M, Mian A and Barber GN: The oncolytic effect of recombinant vesicular stomatitis virus in enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res. 63:8366–8376. 2003.
50.	Obuchi M, Fernandez M and Barber GN: Development of recombinant vesicular stomatitis virus that exploit defects in host defense to augment specific oncolytic activity. J Virol. 77:8843–8856. 2003. View Article : Google Scholar : PubMed/NCBI
51.	Pavio N, Couderc T, Girard S, Sgro JY, Blondel B and Colbère-Garapin F: Expression of mutated poliovirus receptors in human neuroblastoma cells persistently infected with poliovirus. Virology. 274:331–342. 2000. View Article : Google Scholar : PubMed/NCBI